Publications

The hydrogen isotopes deuterium (D) and tritium (T) have become essential tools in chemistry, biology and medicine1. Beyond their widespread use in spectroscopy, mass spectrometry and mechanistic and pharmacokinetic studies, there has been considerable interest in incorporating deuterium into drug molecules1. Deutetrabenazine, a deuterated drug that is promising for the treatment of Huntington’s disease2, was recently approved by the United States’ Food and Drug Administration. The deuterium kinetic isotope effect, which compares the rate of a chemical reaction for a compound with that for its deuterated counterpart, can be substantial1,3,4. The strategic replacement of hydrogen with deuterium can affect both the rate of metabolism and the distribution of metabolites for a compound5, improving the efficacy and safety of a drug. The pharmacokinetics of a deuterated compound depends on the location(s) of deuterium. Although methods are available for deuterium incorporation at both early and late stages of the synthesis of a drug6,7, these processes are often unselective and the stereoisotopic purity can be difficult to measure7,8. Here we describe the preparation of stereoselectively deuterated building blocks for pharmaceutical research. As a proof of concept, we demonstrate a four-step conversion of benzene to cyclohexene with varying degrees of deuterium incorporation, via binding to a tungsten complex. Using different combinations of deuterated and proteated acid and hydride reagents, the deuterated positions on the cyclohexene ring can be controlled precisely. In total, 52 unique stereoisotopomers of cyclohexene are available, in the form of ten different isotopologues. This concept can be extended to prepare discrete stereoisotopomers of functionalized cyclohexenes. Such systematic methods for the preparation of pharmacologically active compounds as discrete stereoisotopomers could improve the pharmacological and toxicological properties of drugs and provide mechanistic information related to their distribution and metabolism in the body.

The large-scale synthesis of the scorpionate ligand Ttz (hydrotris(1,2,4-triazol-1-yl)borate) is reported as well as syntheses of Group VI complexes K[M(L)(CO)3] and M(L)(NO)(CO)2 (L = Ttz or Tp (hydrotris(pyrazol-1-yl)borate), M = Mo or W). The redox characteristics of the metal in these Ttz complexes are shown to be reversibly modulated by interactions between the exo-4-N lone pairs of the triazolyl rings and Brønsted or Lewis acids. The basicity of the scorpionate ligand in [M(Ttz)(CO)3]− is quantified (pKaH2O values range from 1.1 to 4.6) and found to be dependent on both the oxidation state and identity of the metal. In the presence of Brønsted acids, the observed redox behavior for the one-electron oxidation of the Group VI metal center is consistent with a proton-coupled electron transfer (PCET). Indeed, for both Mo and W derivatives, a one-electron oxidation decreases the pKa by ∼3.5 units.